Abstract Number: 789 • 2013 ACR/ARHP Annual Meeting
Sirolimus Plus Prednisone For Erdheim-Chester Disease: A Pilot Trial
Background/Purpose: Erdheim-Chester disease (ECD) is an extremely rare form of non-Langerhans cell histiocytosis. The pathogenesis of ECD is unclear: while most authors suggest the hypothesis…Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…Abstract Number: 791 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Tocilizumab In Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From Cherish
Background/Purpose: Efficacy and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, were previously demonstrated at week 40 of CHERISH, a phase 3 trial in patients…Abstract Number: 792 • 2013 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients
Background/Purpose: Methotrexate polyglutamates (MTX-PG) could be biomarkers of MTX response and adverse effects and could thus be used as a therapeutic drug monitoring (TDM) tool to steer tailor-made therapeutic…Abstract Number: 793 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the…Abstract Number: 794 • 2013 ACR/ARHP Annual Meeting
Recent Trends In Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of TNF Inhibitors
Background/Purpose: The pharmacologic management of JIA has changed dramatically with the advent of tumor necrosis factor inhibitors (TNFi), but the impact of TNFi on medication…Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…Abstract Number: 796 • 2013 ACR/ARHP Annual Meeting
Drug Exposure Limitations of Oral Methotrexate (MTX) At Doses >15mgs May be Overcome By Using a Subcutaneous MTX Auto-Injector in Patients With Rheumatoid Arthritis (RA)
Drug exposure limitations of oral methotrexate (MTX) at doses >15mgs may be overcome by using a subcutaneous MTX auto-injector in pts with rheumatoid arthritis (RA) Background/Purpose:…Abstract Number: 797 • 2013 ACR/ARHP Annual Meeting
Methotrexate Exposure Assessment In Routine Clinical Rheumatology Practice: Effect Of Dosing and Route Of Administration On Polyglutamate Levels
Background/Purpose: Large interpatient variability in Methotrexate (MTX) absorption and intracellular activation to methotrexate polyglutamates (MTXPGs) can explain, in part, the large spectrum of MTX response…Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting
Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …Abstract Number: 801 • 2013 ACR/ARHP Annual Meeting
Remaining Pain Is Common In Early RA Patients Treated With Methotrexate – Results From The EIRA Cohort and The Swedish Rheumatology Quality Register
Background/Purpose: Although treatment with methotrexate is often efficient in decreasing inflammation and joint destruction in RA, several patients report remaining pain at follow-up (Taylor P…Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting
The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis
Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…
ACR Meeting Abstracts